Contract Research
Contract Research reports are the public domain output of consultancy projects that are published with the clients permission when the content is of interest to a wide audience.
Real-World Evidence: Current Best Practice for Reimbursement Decision-Making
15 May 2023
In this report, we discuss best practices for RWE generation and the steps needed to enhance the assessment and use of quality RWE in reimbursement decisions.
Delivering the Triple Win: A Value-Based Approach to Pricing
20 April 2023
In this report, we investigate the theory and practice of value-based pricing in the pharmaceuticals industry, and provide recommendations for how implementation of value-based pricing can be enhanced to deliver the triple win of patient access; healthcare system sustainability; and innovation.
Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechanism
30 March 2023
In this report, we describe the design of a globally aligned, value-based, fully-delinked pull incentive, where payers provide manufacturers with a pre-specified subscription fee based on the value of the antibiotic, regardless of the volume used.
The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe
2 June 2023
In this report, we explore the status of access and uptake for NGS testing for lung cancer in Europe, develop the health economic case for NGS testing, and identify barriers and opportunities for widespread access.
Navigating the Landscape of Digital Health – United Kingdom
16 December 2022
Digital Health Technologies are a major trend in health care, and successfully adding them to the wider portfolio of health technologies requires coordinated involvement from various stakeholders.
Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies
30 November 2022
An increasingly common strategy for treating many cancers is to utilise several medicines with distinct but complementary mechanisms of action in combination or in close sequence…
Supporting the Era of Green Pharmaceuticals in the UK
1 November 2022
This report sets out the high-priority activities that the NHS, UK government and industry should undertake to tackle the challenge of reducing the NHS’s carbon footprint.
Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers
1 June 2022
In recent years, U.S. policymakers have been considering reforms to tackle high and rising prescription drug spending, including unprecedented direct limits on prices and price growth…
Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?
1 June 2022
Gene therapies represent a new era of medicine, offering the potential for truly transformational health gains, and further benefits for society and health systems.